{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:47:26Z","timestamp":1789015646443,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ejmech.2024.117206","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T00:35:14Z","timestamp":1735086914000},"page":"117206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of Ponatinib-based N-Phenylpyrimidine-2-amine derivatives as novel fibroblast growth factor receptor 4 (FGFR4) selective inhibitors"],"prefix":"10.1016","volume":"284","author":[{"given":"Lei","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiecheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7235-2537","authenticated-orcid":false,"given":"Zongjie","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.117206_bib1","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR signaling in cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117206_bib2","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.117206_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd2792","article-title":"The FGF family: biology, pathophysiology and therapy","volume":"8","author":"Beenken","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2024.117206_bib4","doi-asserted-by":"crossref","first-page":"57633","DOI":"10.18632\/oncotarget.9328","article-title":"Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival","volume":"7","author":"Tiong","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2024.117206_bib5","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.7150\/thno.82269","article-title":"FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC","volume":"13","author":"Chen","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2024.117206_bib6","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s10620-013-2609-x","article-title":"Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma","volume":"58","author":"Hyeon","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.ejmech.2024.117206_bib7","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.3390\/curroncol29100626","article-title":"Pemigatinib in intrahepatic cholangiocarcinoma: a work in progress","volume":"29","author":"Gadaleta-Caldarola","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2024.117206_bib8","article-title":"Runx2 is required for the proliferation of osteoblast progenitors and induces proliferation by regulating FGFR2 and FGFR3","volume":"8","author":"Kawane","year":"2018","journal-title":"Sci. Rep-Uk"},{"key":"10.1016\/j.ejmech.2024.117206_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14728222.2021.1976142","article-title":"Hepatocellular carcinoma (HCC): the most promising therapeutic targets in the preclinical arena based on tumor biology characteristics","volume":"25","author":"Wang","year":"2021","journal-title":"Expert. Opin. Ther. Tar."},{"key":"10.1016\/j.ejmech.2024.117206_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.117206_bib11","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/13816128113199990594","article-title":"Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?","volume":"20","author":"Heinzle","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2024.117206_bib12","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1021\/acs.jmedchem.1c01977","article-title":"Discovery of 1,6-naphthyridin-2(1H)-one derivatives as novel, potent, and selective FGFR4 inhibitors for the treatment of hepatocellular carcinoma","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer. Ther."},{"key":"10.1016\/j.ejmech.2024.117206_bib14","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2024.117206_bib15","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-11-0306","article-title":"A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models","volume":"10","author":"Zhao","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2024.117206_bib16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-12-0210","article-title":"FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor","volume":"2","author":"Guagnano","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117206_bib17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/toxsci\/kft161","article-title":"Pan-FGFR inhibition leads to blockade of FGF23 signaling, soft tissue mineralization and cardiovascular dysfunction","volume":"135","author":"Yanochko","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejmech.2024.117206_bib18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.eururo.2020.08.002","article-title":"Hyperphosphatemia secondary to the selective fibroblast growth factor receptor 1\u20133 inhibitor infigratinib (BGJ398) is associated with antitumor efficacy in fibroblast growth factor receptor 3\u2013altered advanced\/metastatic urothelial carcinoma","volume":"78","author":"Lyou","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2024.117206_bib19","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-12-0362","article-title":"Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives","volume":"3","author":"Dieci","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117206_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s003359900703","article-title":"Genomic structure and complete sequence of the human FGFR4 gene","volume":"9","author":"Kostrzewa","year":"1998","journal-title":"Mamm. Genome"},{"key":"10.1016\/j.ejmech.2024.117206_bib21","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1039\/C7MD00213K","article-title":"Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region","volume":"8","author":"Fairhurst","year":"2017","journal-title":"Medchemcomm"},{"key":"10.1016\/j.ejmech.2024.117206_bib22","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1021\/acs.jmedchem.1c01816","article-title":"Design, synthesis, and biological evaluation of 2-formyl tetrahydronaphthyridine urea derivatives as new selective covalently reversible FGFR4 inhibitors","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib23","doi-asserted-by":"crossref","first-page":"6999","DOI":"10.1158\/0008-5472.CAN-17-1865","article-title":"H3B-6527 is a potent and selective inhibitor of FGFR4 in FGF19-driven hepatocellular carcinoma","volume":"77","author":"Joshi","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117206_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117206_bib25","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.117206_bib26","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1038\/s12276-020-00524-4","article-title":"FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma","volume":"52","author":"Huynh","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2024.117206_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113219","article-title":"Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19- driven hepatocellular cancer","volume":"214","author":"Chen","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib28","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1021\/acs.jmedchem.2c00096","article-title":"Design, synthesis, and biological evaluation of aminoindazole derivatives as highly selective covalent inhibitors of wild-Type and gatekeeper mutant FGFR4","volume":"65","author":"Shao","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib29","doi-asserted-by":"crossref","first-page":"7278","DOI":"10.1021\/acs.jmedchem.2c00255","article-title":"Discovery of novel 7-azaindole derivatives as selective covalent gibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma","volume":"65","author":"Zhong","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib30","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib31","first-page":"2013","article-title":"The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells","volume":"7","author":"Zhang","year":"2014","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2024.117206_bib32","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2024.117206_bib33","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejmech.2024.117206_bib34","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.str.2014.09.019","article-title":"Structural insights into FGFR kinase isoform selectivity: diverse binding modes of AZD4547 and ponatinib in complex with FGFR1 and FGFR4","volume":"22","author":"Tucker","year":"2014","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2024.117206_bib35","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1021\/acs.jmedchem.8b01531","article-title":"Fibroblast growth factor receptor 4 (FGFR4) selective inhibitors as hepatocellular carcinoma therapy: advances and prospects","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113794","article-title":"Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors","volume":"225","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib37","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1080\/14756366.2022.2048378","article-title":"6-Amino-2,4,5-trimethylpyridin-3-ol and 2-amino-4,6-dimethylpyrimidin-5-ol derivatives as selective fibroblast growth factor receptor 4 inhibitors: design, synthesis, molecular docking, and anti-hepatocellular carcinoma efficacy evaluation","volume":"37","author":"Chaudhary","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib38","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.1016\/j.bmc.2010.08.042","article-title":"N-Phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases","volume":"18","author":"Oguro","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib39","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1021\/acsomega.9b03223","article-title":"Nicotinamide-ponatinib analogues as potent anti-AML and anti-AML compounds","volume":"5","author":"Larocque","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2024.117206_bib40","article-title":"Advances of fibroblast growth factor\/receptor signaling pathway in hepatocellular carcinoma and its pharmacotherapeutic targets","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.117206_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/cells12071002","article-title":"Role of basic fibroblast growth factor in cancer: biological activity, targeted therapies, and prognostic value","volume":"12","author":"Ardizzone","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2024.117206_bib42","doi-asserted-by":"crossref","first-page":"11484","DOI":"10.1021\/acs.jmedchem.0c00044","article-title":"Development of a potent and specific FGFR4 inhibitor for the treatment of hepatocellular carcinoma","volume":"63","author":"Miranda","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib43","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1021\/jacs.1c13568","article-title":"Covalent proximity scanning of a distal cysteine to target PI3K\u03b1","volume":"144","author":"Borsari","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2024.117206_bib44","doi-asserted-by":"crossref","first-page":"9171","DOI":"10.1021\/acs.jmedchem.5b01018","article-title":"Systematic study of the glutathione (GSH) reactivity of N-arylacrylamides: 1. effects of aryl substitution","volume":"58","author":"Cee","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117298","article-title":"Design, synthesis, and anticancer evaluation of arylurea derivatives as potent and selective type II irreversible covalent FGFR4 inhibitors","volume":"87","author":"Wang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113672","article-title":"Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC","volume":"224","author":"Pan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib47","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1021\/acs.jmedchem.2c01834","article-title":"Development of a covalent inhibitor of c-Jun N-terminal protein kinase (JNK) 2\/3 with selectivity over JNK1","volume":"66","author":"Lu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.117206_bib48","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1002\/jcc.10306","article-title":"Detailed analysis of grid-based molecular docking: a case study of CDOCKER-A CHARMm-based MD docking algorithm","volume":"24","author":"Wu","year":"2003","journal-title":"J. Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424010882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T16:23:37Z","timestamp":1751387017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424010882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":48,"alternative-id":["S0223523424010882"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117206","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of Ponatinib-based N-Phenylpyrimidine-2-amine derivatives as novel fibroblast growth factor receptor 4 (FGFR4) selective inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.117206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117206"}}